Scarica l'app Stockscreener
191.76
1.32%
-2.57
Dopo l'orario di chiusura:
191.80
0.04
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$194.33
Aprire:
$193.92
Volume 24 ore:
2.58M
Relative Volume:
1.44
Capitalizzazione di mercato:
$29.01B
Reddito:
$4.39B
Utile/perdita netta:
$853.00M
Rapporto P/E:
34.80
EPS:
5.5097
Flusso di cassa netto:
$556.00M
1 W Prestazione:
+9.06%
1M Prestazione:
+18.14%
6M Prestazione:
+27.72%
1 anno Prestazione:
+97.39%
Intervallo 1D:
$189.09
$196.66
Intervallo di 1 settimana:
$175.60
$196.66
Portata 52W:
$88.00
$196.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
191.76 | 29.40B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
516.62 | 192.35B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
194.19 | 137.04B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.25 | 44.57B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
281.27 | 40.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.14 | 36.89B | 7.23B | 1.41B | 1.09B | 4.979 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc focuses on sequencing platform innovation as investors weigh long-term growth prospects - AD HOC NEWS
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Illumina stock stays tied to its sequencing business. Investors watch the next filing. - AD HOC NEWS
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Looks To Duck DNA Rival's Renewed Antitrust Case - Law360
Weekly Recap: Axelios challenges Illumina and Guggenheim lifts ILMN target to $200 - TradingView
Illumina, Inc. (ILMN) Stock Analysis: Navigating Potential Downsides Amidst 33.82% ROE - DirectorsTalk Interviews
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR - GlobeNewswire Inc.
iSeq 100 System from Illumina Inc.compact benchtop sequencer targets cost-conscious US labs - AD HOC NEWS
Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board? - simplywall.st
Illumina Inc. focuses on sequencing technology leadership as investors watch long-term growth driver - AD HOC NEWS
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock - Investing.com
Illumina Inc. focuses on sequencing technology as investors assess long-term growth - AD HOC NEWS
Should You Continue to Hold ILMN Stock in Your Portfolio? - TradingView
Price to sales forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
Price to book forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
Form 4 Illumina Inc For: 2 July By Investing.com - Investing.com Canada
Illumina (ILMN) director takes 2026 board fees entirely in stock - Stock Titan
[Form 4] ILLUMINA, INC. Insider Trading Activity - Stock Titan
ILMNIllumina Inc Volatility & Greeks - Finviz
Loomis Sayles Growth Fund's Illumina Inc(ILMN) Holding History - GuruFocus
Illumina Inc (ILMN) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Illumina (ILMN) Gets Bernstein’s Market Perform Rating Amid NovaSeq X Recovery - Insider Monkey
Illumina stock hits 52-week high at 182.98 USD - Investing.com
Illumina stock hits 52-week high at 182.98 USD By Investing.com - Investing.com South Africa
Illumina Inc. focuses on sequencing and clinical genomics as investors watch long term growth - AD HOC NEWS
Piper Sandler raises Illumina stock price target on clinical strength - Investing.com
Why Illumina (ILMN) Stock Is Down Today - Yahoo Finance
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Roche takes on Illumina with new NGS system - MedTech Dive
Illumina: The Operational Turnaround Is Fully Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina earnings outlook and consensus, shares on NASDAQ - AD HOC NEWS
The NextSeq 2000 from Illumina Inc.mid-throughput sequencing aims for everyday lab work - AD HOC NEWS
Illumina Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Roche launches Axelios 1 sequencing platform to rival Illumina - BioWorld News
Roche takes aim at Illumina’s dominance with new gene sequencing machine - WNWN-FM
Roche takes aim at Illumina's dominance with new gene sequencing machine - Reuters
Price to earnings forward of Illumina, Inc. – TURQUOISE:ILMNN - TradingView
Illumina shares hold the 200 day line, analysts stay at Hold - AD HOC NEWS
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip - Yahoo Finance
Roche launches Axelios gene sequencer in a bid to loosen Illumina’s grip - WSAU
Roche Launches AXELIOS 1 Sequencer At $750,000, Targeting Illumina’s Market - insights.citeline.com
Illumina operations and strategy, DNA sequencing leader with NASDAQ-listed shares - AD HOC NEWS
Illumina, Inc. Actuals & Estimates (NASDAQ:ILMN) - TradingView
Illumina at a fresh 52-week high, Bernstein SocGen resumes coverage on the shares - Ad-hoc-news.de
Illumina, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh Actuals & Estimates (BMFBOVESPA:I1LM34) - TradingView
ILMN Forecast — Price Target — Prediction for 2027 - TradingView
Illumina Stock Is Up 32% in 2026: Has the GRAIL Recovery Already Been Priced In? - TIKR.com
Bernstein Maintains Illumina(ILMN.US) With Hold Rating, Announces Target Price $185 - Moomoo
Bernstein SocGen resumes Illumina stock coverage with market perform rating - Investing.com
Illumina chief legal officer sells shares, stock trades near 52-week high - Ad-hoc-news.de
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):